Background. There has been recent debate questioning the efficacy of azithromycin for the treatment of urogenital chlamydia infection. We conducted a meta-analysis to compare the efficacy of 1 g azithromycin with 100 mg doxycycline twice daily (7 days) for the treatment of urogenital chlamydia infection.
A meta-analysis of randomized controlled trials (RCTs) in 2002 reported a 98% cure rate for doxycycline and 97% for azithromycin (difference in efficacy, 1.0%; 95% confidence interval [CI] , −1.0% to 2.0%) [4] . However, 11 of the 12 studies used culture or immunoassay rather than sensitive nucleic acid amplification tests (NAATs) to determine microbiological cure, and one-third had attrition rates >25%. Furthermore, 3 of the studies had cure rates of 81%-92% for azithromycin compared with 99%-100% for doxycycline. Given the use of culture rather than NAATs, it is possible that the reported efficacies were overestimated [5, 6] .
Repeat chlamydia infections are common after treatment; studies report high repeat infection rates ranging from 18% to 34% [7] [8] [9] . As most repeat infections are likely to be reinfections, emerging evidence suggests that treatment failure following azithromycin may account for a substantial proportion [9, 10] , and this has led to considerable debate in the medical and scientific literature [5, 6, [11] [12] [13] . A partner treatment study found that among women who reported having no sex after treatment, 8% (95% CI, 5%-11%) had persistent infection at follow-up [10] ; another study of adolescent females reported a treatment failure of 7.9% (4%-10%) [9] .
Given the recent concerns about the efficacy of azithromycin and the fact that it is >10 years since the meta-analysis by Lau and colleagues [4] , we conducted an updated meta-analysis to compare the efficacy of azithromycin 1 g vs doxycycline 100 mg twice daily for 7 days for the treatment of genital chlamydia infection in men and women.
METHODS
This meta-analysis was conducted according to the PRIMSA (Preferred Reporting Items for Systematic Reviews and MetaAnalyses) statement [14] .
Protocol and Registration
Analysis methods, inclusion criteria, and protocol were registered with Prospective Registration of Systematic Reviews (PROSPERO) under registration number CRD42013003711 (available at: http://www.crd.york.ac.uk/PROSPERO/).
Search Strategy
Medline, PubMed, Embase, Cochrane Controlled Trials Register, Cochrane Reviews, and Cumulative Index to Nursing and Allied Health Literature (CINHAL) were searched from the earliest date up to 31 December 2013. We hand-searched conference abstracts from the International Society for Sexually Transmitted Diseases Research and the International Union Against Sexually Transmitted Infections and the reference lists of identified papers. Only English-language papers were sought.
Search terms included Chlamydia trachomatis OR chlamydia AND azithromycin OR Zithromax. Medical subject headings were used where possible.
Inclusion and Exclusion Criteria
We searched for published RCTs comparing the efficacy of azithromycin 1 g (single dose) with doxycycline 100 mg twice daily for 7 days for treating genital (urethral or cervical) chlamydia infection in men and women. Eligible studies were English-language, included participants aged ≥15 years, and measured microbiological cure (defined as a negative chlamydia test result at the last follow-up) within 3 months of treatment. Studies on treatment of prostatitis in men and pelvic inflammatory disease in women, as well as review and discussion papers, were excluded.
Data Extraction Process
We developed an Excel spreadsheet for extracting the following data: study design, randomization method, participant numbers by treatment arm and sex, presence of signs and/or symptoms at diagnosis, diagnostic method used for assessing microbiological cure, follow-up times, attrition, and microbiological cure. One author (F. Y. S. K.) extracted data from included studies, and the second author (J. S. H.) checked the extracted data. Disagreements were resolved by discussion between the 2 authors and consultation with an additional author (C. K. F.) until a consensus was reached.
Outcome
The primary outcome was the difference in treatment efficacy (efficacy for doxycycline minus efficacy for azithromycin) at the last follow-up confirmed by a microbiological cure-the proportion with microbiological cure; the numerator was the number of treated subjects with a microbiological cure and the denominator was the number of subjects assigned to the treatment and tested. Where available, the cumulative treatment efficacy at the final follow-up was used. For one study [15] , efficacy data were extracted from the modified intention-to-treat analysis. For another study, efficacy data for azithromycin and doxycycline, with and without tinidazole, were used [16] .
Analysis
Meta-analysis was used to calculate the pooled estimates of the difference in treatment efficacy. We used the I 2 test to estimate the proportion of total variability in point estimates that could be attributed to heterogeneity other than by chance [17] . Both fixed and random effects pooled estimates were calculated. Treatment efficacy difference was stratified by sex, signs/ symptoms, type of test (NAAT based vs culture/enzyme immunoassay [EIA], whether the study was double blind, follow-up times (≤3 or >3 weeks), study attrition (calculated as the average attrition across both treatment arms), whether the study was drug company sponsored, whether doxycycline compliance was measured, and when the study was published (before or after 2002). Given the relatively small number of studies in the subgroup analyses, we present both fixed and random effects.
Assessment of Bias and Quality
We assessed publication bias using a funnel plot. Asymmetry was statistically evaluated using the Egger correlation test by regressing the difference in treatment efficacy by its standard error. We used the Cochrane Collaboration Tool to assess bias within studies [18] . Sensitivity analyses were undertaken to investigate the impact of removing studies appearing as outliers in the funnel plot. Data were analyzed using Stata software version 12 (StataCorp, College Station, Texas).
RESULTS

Study Selection
The review process is shown in Figure 1 and the selected papers summarized in Table 1 . Of the 716 references identified, 58 papers were reviewed with 23 studies meeting the inclusion criteria.
Study Characteristics
At the last follow-up visit, 1147 and 912 patients were evaluated for azithromycin and doxycycline efficacy, respectively. Ten studies (43%) included men only [15, 16, 20, 21, 23, 25, 26, 28, 29, 34] , 8 studies (35%) included women only [24, 30, 31, 33, [35] [36] [37] 39] , and 5 studies (22%) included both sexes [19, 22, 27, 32, 38] . Follow-up periods ranged from 1 to 6 weeks; 12 (52%) studies had follow-up times of ≥4 weeks [15, 16, 20, 22, 24, 25, 27-30, 33, 38] . In 16 (70%) studies, the primary aim was to evaluate treatments for nongonococcal urethritis (NGU) or cervicitis with participants being randomized before the causative organisms were diagnosed and only a subgroup being diagnosed with chlamydia [15, 16, 19, 21-26, 28, 29, 31, 34, 35, 37, 39] . In the other 7 studies, the primary aim was to evaluate treatment effect among those diagnosed with chlamydia prior to randomization [20, 27, 30, 32, 33, 36, 38] . Fourteen (61%) studies included only patients with signs and/or symptoms [15, 16, 19, 21, 23-26, 29, 30, 34-37] , with no studies providing results for asymptomatic patients only. Four (17%) studies used EIA or DFA [31, 32, 34, 39] , 6 (26%) used NAAT-based testing [15, 16, 24, 33, 37, 38] , and the remaining 13 (57%) studies used culture to assess [19, 24, 25, 31, 35, 36, 39] , with the remainder based at sexual health clinics. Eight studies (35%) were drug company sponsored [20-23, 28, 29, 32, 37] , and 5 studies (22%) [15, 16, [37] [38] [39] were published after the initial metaanalysis published in 2002 [4] .
Treatment Efficacy
The fixed effects pooled efficacy difference was 2.6% (95% CI, .5%-4.7%) showing a small but significantly greater efficacy for doxycycline, with negligible heterogeneity between studies (I 2 = 1.9%; P = .435). The random effects estimate was 1.5%
(95% CI, −.1% to 3.1%) (Figure 2 ). The fixed effects pooled efficacy for azithromycin was 96.2% (95% CI, 94.9%-97.5%), and the random effects estimate was 94.3% (95% CI, 91.8%-96.8%) ( Figure 3 ). The fixed effects pooled efficacy for doxycycline was 97.4% (95% CI, 96.2%-98.7%), and the random effects estimate was 97.1% (95% CI, 95.6%-98.6%) (Figure 3 ). Heterogeneity between studies was considerably greater for azithromycin efficacy (I 2 = 52.4%; P = .002) than doxycycline efficacy (I 2 = 9.1%; P = .336).
Subgroup analyses (Table 2) found that moderate heterogeneity was associated with men, symptomatic men, doubleblind allocation of treatment, participants with signs or symptoms of chlamydia, NAAT-based testing, follow-up times >3 weeks, attrition between 10% and 19%, measurement of drug compliance, and studies published since 2002. Fixed effect estimates showed significantly higher efficacy for doxycycline in studies of men, in studies of symptomatic men, in studies where NAAT-based testing was used, in studies that were double blind, and in studies published since 2002. No differences in efficacy were observed when stratified by duration of follow-up, attrition, whether drug compliance was measured, in trials based on culture/EIA/DFA, or among women.
Between-Study Bias
The funnel plot (Figure 4 ) showed some asymmetry, with an absence of small studies reporting higher efficacy with doxycycline than azithromycin. It also showed 4 outlier studies-1 large study favoring doxycycline [16] and 3 small studies favoring azithromycin [21, 35, 39] . However, Egger test showed no statistical evidence of publication bias, with a coefficient of .05 (−.60 to .70; P = .874).
Within-Study Bias
All studies reported random sequence generation, but 16 (70%) studies did not provide any information about allocation concealment (Table 3 ). There was a moderate risk of performance bias, with the majority of studies (n = 19 [83%]) being open label. Attrition by treatment arm was available for 15 (65%) studies [15, 16, 19, 22-30, 32, 34, 38] , with 6 studies (26%) [15, 23, 25, 26, 29, 33] reporting attrition rates of ≥20% in each treatment arm. Attrition was comparable between the azithromycin and doxycycline arms (16.7% vs 17.2%, respectively; P = .75) in these 15 studies. Sample size calculations were not provided in 20 (87%) studies, comparison of baseline characteristics between trial arms was provided in 16 (70%) studies [15, 16, 19 
Sensitivity Analysis
Removing the 4 outlier studies had negligible impact on the fixed effects pooled efficacy difference (2.0%; 95% CI, −.0% to 4.1%), but if only the study by Schwebke et al was excluded [16] , the pooled efficacy difference dropped to 1.7% and was no longer statistically significant (95% CI, −.3 to 3.8%) ( Table 4) . Similar results were found in other subgroup analyses where the study by Schwebke et al was excluded.
DISCUSSION
The results of our meta-analysis show a small difference of between 1.5% and 2.6% in favor of doxycycline for the treatment of urogenital chlamydia infection. We also found that doxycycline may be about 7% more effective for the treatment of symptomatic urethral infection in men. The World Health Organization sexually transmitted infection treatment guidelines recommend using treatments with an efficacy >95% [40] , so readers will need to decide whether our results warrant a change to the treatment guidelines. Readers should consider that >80% of chlamydia infections are asymptomatic; the fixed effects estimate of azithromycin efficacy is >95% (96.2%; 95% CI, 94.9%-97.5%); the confidence interval of the more conservative random effects estimate is >95% (94.3%; 95% CI, 91.8%-96.8%), even though the point estimate is <95%; and there are considerable limitations with the quality of available evidence. We found that doxycycline may be more efficacious for urethral infection in men, particularly for those with symptoms. Past studies have found that patients with signs and/or symptoms have higher organism loads [41] [42] [43] [44] , with some suggesting that higher organism load may be related to azithromycin treatment failure. Although the measure of bacterial load in an Australian study was flawed, the study suggested that women with higher organism loads where reinfection had been excluded were more likely to test positive again within 3 months, raising the possibility of treatment failure [7] . A mass azithromycin treatment trial for trachoma observed that 2 months after treatment, 91% of individuals with a low chlamydia organism load at baseline had no infection, whereas only 74% with higher organism loads were infection free at follow-up (P < .01) [45] . Although it is unclear whether antibiotic resistance is a cause for treatment failure, chlamydia isolates demonstrating heterotypic resistance to macrolides (including azithromycin) in vitro have been reported [46, 47] , but only at high, not low, levels of organism load [5, 13, 48] . We found no statistical evidence of publication bias using the Egger test, but the funnel plot showed an absence of published small studies reporting a higher efficacy for doxycycline; it is unclear whether this represents any bias. Our subgroup analyses found some evidence that treatment efficacy favored doxycycline in trials that were not drug company sponsored, raising questions of whether the drug company funding was a source of publication bias [49, 50] .
We found 4 outlying studies in the funnel plot: 3 small studies (<10 subjects in each treatment arm) [21, 35, 39] and 1 larger study by Schwebke et al [16] . Schwebke et al contributed considerable heterogeneity to the pooled efficacy difference and when excluded, the pooled efficacy difference was reduced and nonsignificant (1.7%; 95% CI, −.3% to 3.8%). This study of NGU among men found chlamydia was eradicated in 41 of 53 (77%) men given azithromycin, compared with 55 of 58 (95%) given doxycycline (efficacy difference, 17%; 95% CI, 5%-30%). These results were in sharp contrast to a similar study conducted by Manhart et al in 2013 that found an efficacy difference of 4% (95% CI, −9% to 16%) among men with NGU [15] . Both studies were well designed, included a similar population of men, and were reported according to the Consolidated Standards of Reporting Trials (CONSORT) statement. The main difference was that microbiological cure was reported 3 weeks following treatment in Manhart et al and after 6 weeks in Schwebke et al, although it was measured at both 3 and 6 weeks in this latter study.
We obtained further data from Schwebke and colleagues that showed that men taking doxycycline were more likely to have microbiological cure measured at 3 weeks rather than at 6 weeks as in the azithromycin arm (38% vs 30%; P = .40). Although this was nonsignificant, it does raise the possibility of differential follow-up bias and whether there was a greater risk of reinfection in the azithromycin arm compared with the doxycycline group. However, it could also be argued that measuring cure at 3 weeks rather than 6 weeks might lead to an increased risk of false-positive results due to persistent DNA without viable chlamydia [51] . This does highlight the importance of ensuring that trial arms are comparable particularly with respect to follow-up and outcome measurement and ascertainment.
We would expect to find that the efficacy difference in favor of doxycycline has increased since the last meta-analysis in 2002 [4] , if increased antibiotic resistance is contributing to azithromycin treatment failure for chlamydia, as has been observed for Mycoplasma genitalium [52] . Our data suggest that efficacy may have increased since 2002 to be between 4.4% and 6.9% higher for doxycycline, but these results were not significant, there was moderate heterogeneity in the studies and the results were very sensitive to the inclusion of the study by Schwebke and colleagues. However, there have been only 5 studies published since the last meta-analysis [15, 16, [37] [38] [39] , and this smaller sample size (151 in the azithromycin group and 149 in the doxycycline group) may have reduced the statistical power to find a significant efficacy difference.
There are a number of limitations in our meta-analysis. First, it was limited to published, English-language studies, which could limit the generalizability of our findings. We were unsuccessful in obtaining results from 2 drug company-sponsored studies that found no difference in efficacy between azithromycin and doxycycline [53] . Some of our subgroup analyses were based on a small number of studies, and although the I 2 test for heterogeneity only reached statistical significance for 2 subgroups (>3 weeks of follow-up and attrition of 10%-20%), moderate, but non-statistically significant heterogeneity was observed for several subgroups (men, symptomatic individuals, studies using NAATs, studies where compliance was measured, studies published since 2002). The strengths of our metaanalysis are that we looked for bias within and between studies, and we conducted a comprehensive subgroup and sensitivity analyses to investigate whether our pooled estimates were robust. The quality of the studies varied considerably. Only 4 studies were double blind, placebo controlled [15, 16, 23, 29] , and when treatment regimens differ substantially as they do here (single dose vs dosing for 7 days), this can dramatically bias the results. It is possible that individuals taking 7 days of doxycycline may delay resuming sex while they are on treatment, whereas individuals taking single-dose azithromycin may resume sex earlier, making them more susceptible to reinfection. If this happened, we would expect to see a higher efficacy for doxycycline. Most studies did not provide sample size estimates, and in nearly twothirds of studies, chlamydia was only a secondary outcome and may not have been adequately powered to find a difference if it existed. Further, the majority of studies were among high-risk populations, usually sexual health clinic patients; several studies included symptomatic patients only; and there were few data available for women, reducing the generalizability of the results. The relative efficacy of doxycycline vs azithromycin in a more general, largely asymptomatic population remains unclear. Only 7 studies measured pill compliance [16, 22, 24, 29, 32, 33, 37] , even when compliance with doxycycline has previously shown to be poor. If doxycycline compliance was poor [54] in these studies, we would have expected that the difference in efficacy to favor azithromycin, although partial compliance with doxycycline has been reported to produce high cure rates [3] .
Importantly we were unable to find any RCTs comparing doxycycline and azithromycin for the treatment of rectal chlamydia infection, despite reports of treatment failure of up to 13% following treatment with 1 g azithromycin [55, 56] . Given the potential risk of human immunodeficiency virus transmission associated with rectal chlamydia infection, it is vital that efficacious treatment be made available [57] . Given these concerns, the European guidelines currently recommend that chlamydia rectal infection be treated with 7 days of doxycycline [58] .
CONCLUSIONS
Our meta-analysis showed that there may be a small increased treatment efficacy of up to 3% in favor of doxycycline for the treatment of urogenital chlamydia and about 7% increased efficacy for doxycycline for the treatment of symptomatic urethral infection in men. In considering whether a change to the treatment guidelines is warranted, readers should consider that >80% of chlamydia infections are asymptomatic and that there are considerable limitations with the quality of available evidence. Given increasing concern about possible azithromycin treatment failure, further well-designed double-blind, placebo-controlled RCTs are warranted. Similarly, RCTs addressing rectal chlamydia infections are also urgently needed.
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